Journal
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
Volume 36, Issue 3, Pages 637-645Publisher
WILEY
DOI: 10.1111/jgh.15185
Keywords
biologics; chronic ulcerative colitis; Clostridium difficile; Crohn's disease; cytomegalovirus; inflammatory bowel disease; intestinal tuberculosis
Categories
Ask authors/readers for more resources
The article discusses the increased incidence and prevalence of inflammatory bowel disease (IBD) in Asian countries, as well as the recommendations for medical management of IBD in Asia. These recommendations cover various aspects from pretreatment evaluation to treatment management.
Inflammatory bowel disease (IBD) has increased in incidence and prevalence in Asian countries since the end of the 20th century. Moreover, differences in the cause, phenotypes, and natural history of IBD between the East and West have been recognized. Therefore, the Asian Organization for Crohn's and Colitis and the Asia Pacific Association of Gastroenterology have established recommendations on medical management of IBD in Asia. Initially, the committee members drafted 40 recommendations, which were then assessed according to Grading of Recommendations Assessment, Development and Evaluation. Eight statements were rejected as this indicated that consensus had not been reached. The recommendations encompass pretreatment evaluation; medical management of active IBD; medical management of IBD in remission; management of IBD during the periconception period and pregnancy; surveillance strategies for colitis-associated cancer; monitoring side effects of thiopurines and methotrexate; and infections in IBD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available